Compare Citius Pharmaceuticals Inc (CTXR) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Kaltura Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Kaltura Inc trades at $1.6 (market cap $249.42M). The key difference: Kaltura Inc is far larger — about 12.5× Citius Pharmaceuticals Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | KLTR | |
|---|---|---|
Market Cap | $20.01M | $249.42M |
Sector | Health | Technology |
52-Week High | $1.82 | $1.89 |
52-Week Low | $0.48 | $1.08 |
Enterprise Value | $16.23M | $261.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Kaltura (KLTR) trades at $1.61, down 1.83% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported Q2 2026 earnings that beat expectations, with revenue stable around $181 million and improving net loss margins. Recent news highlights leadership in virtual event platforms and AI technology awards, alongside significant insider selling in August 2026.
The outlook is mixed: analyst consensus leans buy (44.45%) with strong gross margins (72.05%), but persistent net losses and high valuation ratios (EV/EBITDA 336.29) pose risks. Investment opportunity hinges on AI product growth and cost management, while execution risks and cash flow volatility remain concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
